Multi-domain fusion protein and application thereof

By developing multi-domain fusion proteins containing anti-PD-L1, antagonistic VEGF and TGF-β binding fragments, anti-VEGF monoclonal antibody, anti-PD-1/PD-L1 monoclonal antibody and TGF-β antagonist in the prior art were solved. The lack of combination has achieved effective tumor-inhibiting effects on a variety of cancers.

CN118909140APending Publication Date: 2024-11-08ZHEJIANG DOER BIOLOGICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411001710.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-02-22
Filing Date
2022-02-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the combination of anti-VEGF monoclonal antibody, anti-PD-1/PD-L1 monoclonal antibody and TGF-β antagonist has not been reported, and it is difficult to effectively inhibit tumor microangiogenesis and immune escape.

Method used

Develop a multi-domain fusion protein containing anti-PD-L1 single domain antibody fragments, antagonistic VEGF fragments and TGF-β binding fragments to block PD-L1/PD-1 interactions, reduce microvascular growth and clear tumor microenvironment Excess TGF-β in it enhances the immune response.

Benefits of technology

This fusion protein can significantly inhibit tumor growth and improve the killing function of T cells on tumor cells, which is significantly better than the tumor inhibitory effect of single drug in multiple cancer models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004961752870000101
    Figure BDA0004961752870000101
  • Figure BDA0004961752870000111
    Figure BDA0004961752870000111
  • Figure BDA0004961752870000132
    Figure BDA0004961752870000132
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a multi-structural-domain fusion protein with anticancer activity, a preparation method of the multi-structural-domain fusion protein and application of the multi-structural-domain fusion protein in preparation of drugs for treating tumors. The invention provides a fusion protein. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, an antagonistic VEGF fragment and a TGF-beta binding fragment. The multi-structural-domain fusion protein with anticancer activity provided by the invention can block PD-L1 / PD-1 interaction by the anti-PD-L1 monoclonal antibody in an antibody fusion protein molecule, and the anti-VEGF monoclonal antibody can reduce microvascular growth and inhibit metastatic diseases, so that the anti-tumor activity of the multi-structural-domain fusion protein is improved, and the anti-tumor activity of the multi-structural-domain fusion protein is improved. And the TGF-beta receptor is organically combined with the functions of relieving the tolerance of cancer cells to TGF-beta signals and enhancing immune response, so that the TGF-beta receptor can be used for treating tumors and has a good industrial prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a multi-domain fusion protein with anti-cancer activity and a preparation method and use thereof. Background Art

[0002] One of the differences between tumor cells and normal cells is the high metabolic demand for their growth. Tumor cells rely on blood vessels to provide nutrients and oxygen, process metabolites, and promote the formation of new blood vessels on existing blood vessels. Among the pro-angiogenic factors secreted by tumors, human vascular endothelial growth factor (VEGF), especially VEGF-A, is an important factor leading to tumor angiogenesis (Josep Garcia et al., 2020, Cancer Treatment Reviews 86: 1-2). Therefore, inhibition of the VEGF signaling pathway can limit the progression of many tumors. For example, bevacizumab (trade name ), a humanized anti-VEGF monoclonal antibody that binds to VEGF and prevents VEGF from interacting with VEGF receptors (Flt-1 and KDR) on the surface of endothelial cells. Bevacizumab is currently approved by the FDA for the treatment of metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer and recurrent glioblastoma.

[0003] Transforming growth factor (TGF-β) is a cytokine that maintains tissue homeostasis by regulating cell growth, differentiation, proliferation, and survival. Although the TGF-β pathway can control tumors by promoting cell cycle arrest and apoptosis in the early stages of tumors, in the late stages of tumors, TGF-β can also inhibit cytotoxic T cells and promote cancer cell proliferation, invasion, and metastasis, ultimately causing tumor escape. This functional conversion is known as the "TGF-β paradox." The TGFβ signaling pathway induces T H 1 cells differentiate into Tregs, weaken the activation of CD8+ effector T cells, and limit the development of central memory T cells, fundamentally affecting the function of tumor-infiltrating T cells. In mammals, TGF-β mainly has three subtypes: TGF-β1, TGF-β2, and TGF-β3. By expressing TGF-β at high levels, tumors are protected from immune surveillance. Consistent with this, non-small cell lung cancer (NSCLC), renal cell carcinoma (CRC), gastric cancer, and prostate cancer with high expression of TGF-β are all associated with tumor progression and poor prognosis (Marin-Acevedo et al., Journal of Hematology & Oncology, 11:39, 2018). This shows that TGF-β antagonism will be a potential new direction for tumor treatment.

[0004] Currently, anti-PD-1 / PD-L1 monoclonal antibodies as immune checkpoint inhibitors have been widely used in tumor treatment. M7824, a fusion of anti-PD-L1 monoclonal antibody Avelumab and TGF-β receptor II (TGF-βTrap), has entered the clinical stage. However, the combination of anti-PD-1 / PD-L1 monoclonal antibodies, TGF-β antagonists and anti-VEGF monoclonal antibodies has not yet been reported. Summary of the invention

[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a multi-domain fusion protein with anti-cancer activity and a preparation method and use thereof, so as to solve the problems in the prior art.

[0006] To achieve the above objectives and other related objectives, the present invention provides a fusion protein on the one hand, which includes an anti-PD-L1 single domain antibody fragment, an antagonist VEGF fragment, and a TGF-β binding fragment.

[0007] Another aspect of the present invention provides an isolated polynucleotide encoding the above-mentioned fusion protein.

[0008] Another aspect of the present invention provides a construct comprising the isolated polynucleotide described above.

[0009] Another aspect of the present invention provides an expression system, which contains the above-mentioned construct or the above-mentioned polynucleotide integrated into the genome.

[0010] Another aspect of the present invention provides a method for preparing the above-mentioned fusion protein, comprising: culturing the above-mentioned expression system under appropriate conditions to express the fusion protein, and isolating and purifying to provide the fusion protein.

[0011] Another aspect of the present invention provides use of the above fusion protein or the culture of the above expression system in preparing a drug.

[0012] Another aspect of the present invention provides a pharmaceutical composition, comprising the above fusion protein, or a culture of the above expression system. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 Area under the plasma concentration-time curve of TAF-6 and Avastin;

[0014] Figure 2 The anti-tumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized MDA-MB-231 breast cancer subcutaneous xenograft model;

[0015] Figure 3The anti-tumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized MDA-MB-231 breast cancer subcutaneous xenograft model;

[0016] Figure 4 The anti-tumor efficacy of multi-domain fusion protein TAF-6, M7824 analogs, and Avastin in the PBMC immune system humanized MDA-MB-231 breast cancer subcutaneous transplant tumor model;

[0017] Figure 5 The anti-tumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized Calu-6 lung cancer subcutaneous transplant model;

[0018] Figure 6 The anti-tumor efficacy of multi-domain fusion protein TAF-6, M7824 analogs, and Avastin in the PBMC immune system humanized Calu-6 lung cancer subcutaneous transplant tumor model;

[0019] Figure 7 The anti-tumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized HCT116 colon cancer subcutaneous transplant model;

[0020] Figure 8 The anti-tumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized Huh-7 liver cancer subcutaneous transplant tumor model;

[0021] Fig. 9 The anti-tumor efficacy of multi-domain fusion protein TAF-6, M7824 analogs, and Avastin in the PBMC immune system humanized Huh-7 liver cancer subcutaneous transplant tumor model;

[0022] Fig.10 Antitumor efficacy of multi-domain fusion proteins in the PBMC immune system humanized HT1080 sarcoma subcutaneous xenograft model. DETAILED DESCRIPTION

[0023] After extensive exploration and research, the inventors of the present invention unexpectedly discovered a fusion protein molecule that can combine the functions of anti-PD-L1 monoclonal antibody to block PD-L1 / PD-1 interaction, antagonistic VEGF monoclonal antibody to reduce microvascular growth and inhibit metastatic disease, and TGF-β receptor to improve T cell dysfunction caused by TGF-β in the tumor microenvironment and enhance immune response, and has excellent tumor inhibition effect. The present invention was completed on this basis.

[0024] The first aspect of the present invention provides a fusion protein, which includes an anti-PD-L1 single domain antibody fragment, an antagonist VEGF fragment, and a TGF-β binding fragment. In the above-mentioned fusion protein, the anti-PD-L1 single domain antibody fragment can generally be used to block the PD-L1 / PD-1 interaction, increase the expression of IFN-γ and / or IL-2 in T lymphocytes, and thus inhibit tumor growth. The antagonist VEGF fragment can generally include an Fc portion that can bind to the FcRn receptor, thereby prolonging the half-life in vivo, and can also bind to effector cells expressing Fc receptors to kill cancer cells. The TGF-β binding fragment can improve the killing function of tumor-infiltrating T cells on tumor cells by clearing overexpressed TGF-β in the tumor microenvironment.

[0025] The fusion protein provided by the present invention may include an anti-PD-L1 single domain antibody fragment. The above-mentioned anti-PD-L1 single domain antibody fragment may generally be a polypeptide or protein fragment that can specifically bind to PD-L1. In the anti-PD-L1 single domain antibody fragment, the corresponding antibody light chain is usually missing, and only the fragment corresponding to the heavy chain variable region is present. The binding properties of the anti-PD-L1 single domain antibody fragment can generally be determined by the three complementarity determining regions (CDRs) included therein, and the CDR region can be arranged in order with the framework region (FR, framework region), and the FR region does not directly participate in the binding reaction. These CDRs can form a ring structure, and the β-folds formed by the FRs therebetween are close to each other in the spatial structure, forming the antigen binding site of the antibody. For example, the complementarity determining region (CDR) of the above-mentioned anti-PD-L1 single domain antibody fragment may include an amino acid sequence such as CDR1 shown in one of SEQ ID NO.1 to 5, CDR2 shown in one of SEQ ID NO.6 to 9, and CDR3 shown in one of SEQ ID NO.10 to 15.

[0026] In a specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.1, CDR2 with an amino acid sequence as shown in SEQ ID NO.6, and CDR3 with an amino acid sequence as shown in SEQ ID NO.10.

[0027] In another specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.2, CDR2 with an amino acid sequence as shown in SEQ ID NO.7, and CDR3 with an amino acid sequence as shown in SEQ ID NO.11.

[0028] In another specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.3, CDR2 with an amino acid sequence as shown in SEQ ID NO.7, and CDR3 with an amino acid sequence as shown in SEQ ID NO.12.

[0029] In another specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.4, CDR2 with an amino acid sequence as shown in SEQ ID NO.8, and CDR3 with an amino acid sequence as shown in SEQ ID NO.13.

[0030] In another specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.2, CDR2 with an amino acid sequence as shown in SEQ ID NO.7, and CDR3 with an amino acid sequence as shown in SEQ ID NO.14.

[0031] In another specific embodiment of the present invention, the complementarity determining region of the anti-PD-L1 single domain antibody fragment includes: CDR1 with an amino acid sequence as shown in SEQ ID NO.5, CDR2 with an amino acid sequence as shown in SEQ ID NO.9, and CDR3 with an amino acid sequence as shown in SEQ ID NO.15.

[0032] The above-mentioned anti-PD-L1 single-domain antibody fragment may also include a framework region (FR). As described above, the CDR region may be arranged in order with the FR region. For example, the anti-PD-L1 single-domain antibody fragment may include FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from the N-terminus to the C-terminus. The framework region FR includes FR1 whose amino acid sequence may be as shown in SEQ ID No.49, FR2 whose amino acid sequence is as shown in one of SEQ ID Nos.50 to 52, FR3 whose amino acid sequence is as shown in one of SEQ ID Nos.53 to 55, and FR4 whose amino acid sequence is as shown in SEQ ID No.56.

[0033] In a specific embodiment of the present invention, the frame region FR includes:

[0034] The amino acid sequence is FR1 shown in SEQ ID NO.49, FR2 shown in SEQ ID NO.50, FR3 shown in SEQ ID NO.53; FR4 shown in SEQ ID NO.56, or

[0035] The amino acid sequence is FR1 shown in SEQ ID NO.49, FR2 shown in SEQ ID NO.51, FR3 shown in SEQ ID NO.54; FR4 shown in SEQ ID NO.56, or

[0036] The amino acid sequence is FR1 shown in SEQ ID NO.49, FR2 shown in SEQ ID NO.52, FR3 shown in SEQ ID NO.54; FR4 shown in SEQ ID NO.56, or

[0037] The amino acid sequence is FR1 shown in SEQ ID NO.49, FR2 shown in SEQ ID NO.52, FR3 shown in SEQ ID NO.55; and FR4 shown in SEQ ID NO.56.

[0038] In another specific embodiment of the present invention, the anti-PD-L1 single domain antibody fragment may include: a) a polypeptide fragment whose amino acid sequence is shown in one of SEQ ID Nos. 16 to 21; or, b) a polypeptide fragment whose amino acid sequence has a sequence identity of more than 80% with one of SEQ ID Nos. 16 to 21 and has the function of the polypeptide fragment specified in a). Specifically, the polypeptide fragment in the above b) specifically refers to: an amino acid sequence such as an amino acid sequence shown in one of SEQ ID Nos. 16 to 21, obtained by substitution, deletion or addition of one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids, or a polypeptide fragment obtained by adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids to the N-terminus and / or C-terminus, and having the functions of a polypeptide fragment as shown in one of SEQ ID Nos. 16 to 21, for example, it may be the ability to specifically bind to PD-L1, it may be the ability to block the PD-L1 / PD-1 interaction, thereby blocking the PD-L1 / PD1 pathway, it may be the function of increasing the expression of IFN-γ and / or IL-2 in T lymphocytes, or it may be the function of inhibiting tumor growth. The amino acid sequence of the anti-PD-L1 single domain antibody fragment in b) above may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more identity with one of SEQ ID No. 16 to 21. The anti-PD-L1 single domain antibody fragment may generally be derived from alpaca (Vicugna pacos), for example, its CDR region may be derived from alpaca. The anti-PD-L1 single domain antibody fragment may generally be humanized, for example, its framework region may be derived from human.

[0039] Herein, sequence identity refers to the percentage of identical residues in the sequences involved in the comparison. The sequence identity of two or more sequences can be calculated using calculation software well known in the art, such as those available from NCBI.

[0040] The fusion protein provided by the present invention may include an antagonist VEGF fragment. The antagonist VEGF fragment may generally be a polypeptide or protein fragment capable of antagonizing VEGF. For example, the antagonist VEGF fragment may be a monoclonal antibody, etc. For another example, the antagonist VEGF fragment may be bevacizumab, etc.

[0041] In a specific embodiment of the present invention, the antagonist VEGF fragment may include:

[0042] c) a polypeptide fragment whose amino acid sequence is shown in one of SEQ ID No. 22 to 23;

[0043] d) A polypeptide fragment having an amino acid sequence with more than 80% sequence identity with one of SEQ ID No. 22 to 23 and having the function of the polypeptide fragment defined in c). Specifically, the amino acid sequence in the above d) specifically refers to: an amino acid sequence as shown in one of SEQ ID Nos. 22 to 23 obtained by substitution, deletion or addition of one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or an amino acid sequence as shown in one of SEQ ID Nos. 22 to 23 obtained by adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids to the N-terminus and / or C-terminus, and a polypeptide fragment having the functions of a polypeptide fragment as shown in one of SEQ ID Nos. 22 to 23, for example, it can be a function of antagonizing VEGF, and it can also be a function of the Fc part that binds to the FcRn receptor, thereby prolonging the half-life in vivo, and it can also bind to effector cells expressing Fc receptors to kill cancer cells. The amino acid sequence in d) may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more identity with one of SEQ ID No. 22 to 23. The above-mentioned antagonistic VEGF fragment may generally be derived from mice (Mus musculus), for example, its CDR region may be derived from mice. The above-mentioned antagonistic VEGF fragment may generally be humanized, for example, its framework region may be derived from humans.

[0044] The fusion protein provided by the present invention may include a TGF-β binding fragment. The above-mentioned TGF-β binding fragment can usually specifically bind to each TGF-β isoform (for example, TGF-β1, TGF-β2 and TGF-β3, etc.), and TGF-β isoforms are usually highly expressed in a variety of malignant tumors, which may be one of the important factors leading to poor clinical treatment effects. For example, the TGF-β binding fragment can be a TGF-βRⅡ (TGF-β receptor II) extracellular region structural fragment.

[0045] In a specific embodiment of the present invention, the TGF-β binding fragment may include:

[0046] e) a polypeptide fragment whose amino acid sequence is shown in SEQ ID No.24;

[0047] f) A polypeptide fragment having an amino acid sequence with more than 80% sequence identity with SEQ ID No. 24 and having the function of the polypeptide fragment defined in e). Specifically, the amino acid sequence in the above f) specifically refers to: the amino acid sequence as shown in SEQ ID No. 24 obtained by replacing, deleting or adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids at the N-terminus and / or C-terminus, and a polypeptide fragment having the function of the polypeptide fragment as shown in SEQ ID No. 24, for example, can bind to various TGF-β isomers (for example, TGF-β1, TGF-β2 and TGF-β3, etc.), thereby clearing overexpressed TGF-β in the tumor microenvironment, and can also improve the killing function of tumor-infiltrating T cells on tumor cells. The amino acid sequence in f) may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more identity with SEQ ID No. 24. The TGF-β binding fragment may generally be derived from human (homo sapiens).

[0048] The fusion protein provided by the present invention may also include a connecting peptide fragment. In the fusion protein, a plurality of connecting peptide fragments may be generally included, and connecting peptide fragments may be provided between at least part of the domains or each domain. For example, a connecting peptide may be provided between an anti-PD-L1 single domain antibody fragment and an antagonist VEGF fragment. For another example, a connecting peptide may be provided between an antagonist VEGF fragment and a TGF-β binding fragment. The above-mentioned connecting peptide fragment may generally be a flexible polypeptide rich in G, S and / or A (mainly composed of glycine (G), serine (S) and / or alanine (A)) of suitable length, so that adjacent protein domains can move freely relative to each other. For example, the amino acid sequence of the connecting peptide fragment may include sequences such as (GS) n, (GGS) n, (GGSG) n, (GGGS) nA, (GGGGS) nA, (GGGGS) nG, (GGGGA) nA, (GGGGG) nA, etc., wherein n is selected from an integer between 1-10. In a specific embodiment of the present invention, the length of the amino acid sequence of the connecting peptide fragment can be 3-30, 3-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24, 24-26, 26-28, or 28-30. In a more preferred specific embodiment of the present invention, the connecting peptide fragment can include a polypeptide fragment with an amino acid sequence as shown in one of SEQ ID NOs. 34-36.

[0049] In the fusion protein provided by the present invention, the fusion protein can be linear, for example, the fusion protein can include an anti-PD-L1 single domain antibody fragment, an antagonist VEGF fragment, and a TGF-β binding fragment in sequence from the N-terminus to the C-terminus. The fusion protein can also have a structure similar to that of a monoclonal antibody, for example, the anti-PD-L1 single domain antibody fragment can be located at the N-terminus of the heavy chain of the antagonist VEGF fragment, for example, the anti-PD-L1 single domain antibody fragment can be located at the N-terminus of the light chain of the antagonist VEGF fragment, for example, the TGF-β binding fragment can be located at the C-terminus of the heavy chain of the antagonist VEGF fragment. In a specific embodiment of the present invention, the amino acid sequence of the fusion protein may include a sequence shown in SEQ ID NO.23, or one of SEQ ID NOs.25-33. For example, the amino acid sequence of the fusion protein may include a sequence shown in SEQ ID NO.25 and SEQ ID NO.26, a sequence shown in SEQ ID NO.25 and SEQ ID NO.27, a sequence shown in SEQ ID NO.25 and SEQ ID NO.28, a sequence shown in SEQ ID NO.25 and SEQ ID NO.29, a sequence shown in SEQ ID NO.30 and SEQ ID NO.27, a sequence shown in SEQ ID NO.30 and SEQ ID NO.29, a sequence shown in SEQ ID NO.31 and SEQ ID NO.23, a sequence shown in SEQ ID NO.32 and SEQ ID NO.23, or a sequence shown in SEQ ID NO.33 and SEQ ID NO.23.

[0050] The second aspect of the present invention provides an isolated polynucleotide encoding the fusion protein provided in the first aspect of the present invention. The above polynucleotide can be RNA, DNA or cDNA, etc. The method of providing the isolated polynucleotide should be known to those skilled in the art. For example, it can be prepared by automatic DNA synthesis and / or recombinant DNA technology, or it can be isolated from a suitable natural source.

[0051] The third aspect of the present invention provides a construct, which contains the isolated polynucleotide provided in the second aspect of the present invention. Suitable methods for constructing the above construct should be known to those skilled in the art. For example, the construct can be constructed by in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology and the like, and more specifically, can be constructed by inserting the above isolated polynucleotide into the multiple cloning site of the expression vector. The expression vector in the present invention generally refers to various commercially available expression vectors well known in the art, such as bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors. Generally speaking, a suitable vector can contain a replication origin, a promoter sequence, a convenient restriction enzyme site and one or more selectable markers that function in at least one organism. For example, these promoters can include but are not limited to the lac or trp promoter of Escherichia coli; the λ phage PL promoter; the eukaryotic promoter includes the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the methanol oxidase promoter of Pichia pastoris and other known promoters that can control the expression of genes in prokaryotic or eukaryotic cells or their viruses. Marker genes can be used to provide phenotypic traits for selecting transformed host cells, for example, can include but are not limited to dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli, etc. When the polynucleotide is expressed, the expression vector can also include an enhancer sequence. If the enhancer sequence is inserted into the vector, transcription will be enhanced. The enhancer is a cis-acting factor of DNA, usually about 10 to 300 base pairs, which acts on the promoter to enhance gene transcription.

[0052] The fourth aspect of the present invention provides an expression system, which contains the construct provided by the third aspect of the present invention or the polynucleotide provided by the second aspect of the present invention integrated into the genome, so as to express the above-mentioned fusion protein. The above-mentioned expression system can be a host cell, and any cell suitable for expression by an expression vector can be used as a host cell, for example, the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; a filamentous fungal cell, or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast, filamentous fungi, plant cells; insect cells of Drosophila S2 or Sf9; animal cells such as CHO, COS, 293 cells, or Bowes melanoma cells, etc. The method of introducing the construct into the host cell should be known to those skilled in the art, for example, microinjection, gene gun method, electroporation method, virus-mediated transformation method, electron bombardment method, calcium phosphate precipitation method and the like.

[0053] The fifth aspect of the present invention provides a method for preparing the fusion protein provided in the first aspect of the present invention. A person skilled in the art may select a suitable method to prepare the fusion protein. For example, the preparation method may include: culturing the expression system provided in the fourth aspect of the present invention under suitable conditions to express the fusion protein, collecting the culture containing the fusion protein, and then separating and purifying to provide the fusion protein.

[0054] The sixth aspect of the present invention provides the use of the fusion protein provided in the first aspect of the present invention and the culture of the expression system provided in the fourth aspect of the present invention in the preparation of a drug. The above-mentioned drug can be a drug for treating a tumor, for example, it can be a cancer or a solid tumor, specifically lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin's lymphoma, hematological malignancies, sarcoma, head and neck cancer and nasopharyngeal carcinoma, etc. These cancers can be early, middle or late, such as metastatic cancer, etc.

[0055] The seventh aspect of the present invention provides a pharmaceutical composition, including the fusion protein provided in the first aspect of the present invention or the culture of the expression system provided in the fourth aspect of the present invention. In the above-mentioned pharmaceutical composition, the content of the fusion protein or culture is generally a therapeutically effective amount. In the present invention, "therapeutically effective amount" generally refers to an amount that can reduce the severity of disease symptoms, increase the frequency and duration of disease asymptomatic periods, or prevent damage or disability caused by disease pain after an appropriate administration period. The ability to inhibit tumor growth can be evaluated in an animal model system that predicts the efficacy of human tumors. Alternatively, it can also be evaluated by examining the ability to inhibit cell growth, and this inhibition can be determined in vitro by tests known to those skilled in the art. A therapeutically effective amount of fusion protein or pharmaceutical composition can generally reduce tumor size or otherwise alleviate the symptoms of the subject. Those skilled in the art can select a suitable therapeutically effective amount according to actual conditions, for example, the size of the subject, the severity of the subject's symptoms, and the selected specific composition or route of administration. The prescription for treatment (for example, the determination of the dosage, etc.) can be determined by a doctor, and factors generally considered include but are not limited to the disease being treated, the condition of the individual patient, the delivery site, the method of administration, and other factors.

[0056] The pharmaceutical composition provided by the present invention may also include a pharmaceutically acceptable carrier. The above-mentioned carrier may include various excipients and diluents, which are not necessary active ingredients themselves and have no excessive toxicity after administration. Suitable carriers should be well known to those skilled in the art, for example, a full discussion of pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ, 1991).

[0057] The eighth aspect of the present invention provides a treatment method, comprising: administering to an individual a therapeutically effective amount of the fusion protein provided by the first aspect of the present invention, the culture of the expression system provided by the fourth aspect of the present invention, or the pharmaceutical composition provided by the seventh aspect of the present invention.

[0058] In the present invention, the term "treatment" includes preventive, curative or palliative operations that can lead to desired pharmaceutical and / or physiological effects. A better treatment effect means that one or more symptoms of the disease can be reduced or the disease can be completely eliminated, or the occurrence of the disease can be blocked or delayed and / or the risk of disease development or deterioration can be reduced.

[0059] In the present invention, "individual" generally includes humans, non-human primates, or other mammals (such as dogs, cats, horses, sheep, pigs, cows, etc.), which can benefit from treatment using the preparation, kit or combined preparation.

[0060] In the present invention, the above-mentioned fusion protein, culture of expression system, or pharmaceutical composition can be used as a single active ingredient, or can be used in combination with other agents for administration in combination therapy. For example, the above-mentioned multi-domain fusion protein with anti-cancer activity, culture of expression system, or pharmaceutical composition can be combined with at least one other anti-tumor drug. For another example, the above-mentioned multi-domain fusion protein with anti-cancer activity, culture of expression system, or pharmaceutical composition can be used in combination with antibodies targeting other tumor-specific antigens.

[0061] The multi-domain fusion protein with anti-cancer activity provided by the present invention can organically combine the functions of anti-PD-L1 monoclonal antibody to block PD-L1 / PD-1 interaction, anti-VEGF monoclonal antibody to reduce microvascular growth and inhibit metastatic disease, and TGF-β receptor to relieve cancer cells' tolerance to TGF-β signals and enhance immune response in one antibody fusion protein molecule, thereby being used to treat tumors and having good industrial prospects.

[0062] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0063] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0064] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0065] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields. These techniques are well described in the literature, see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; these series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATINSTRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999. BIOLOGY, Vol. 119, Chromatin Protocols (PB Becker, ed.) Humana Press, Totowa, 1999, etc.

[0066] Example 1 Construction and recombinant expression of fusion protein

[0067] According to the codon preference of CHO cells, the amino acid sequence of the multi-domain fusion protein in Table 1, PD-L1-Fc fusion protein (SEQ ID NO.47) and Fc-TGFβRII fusion protein (SEQ ID NO.48) were converted into base sequences, and HindIII restriction site and Kozak sequence (GCCACC) were introduced at the 5' end of the heavy chain and light chain coding sequences, respectively, and a stop codon and EcoRI restriction site were introduced at the 3' end to obtain full-length DNA by gene synthesis (General Biosystems (Anhui) Co., Ltd.). The synthesized heavy chain and light chain coding genes were double-digested with HindIII-HF (purchased from NEB, R3104V) and EcoRI-HF (purchased from NEB, R3101V), respectively, and the agarose gel DNA / PCR product small-scale recovery kit (purchased from Biomiga) was used for gel excision and recovery, and the pCDNA3.1 (+) vector that was also double-digested with HindIII and EcoRI was connected with T4 ligase (purchased from NEB, M0202V), transformed into Top10 competent cells, and plated on LB ampicillin resistance plates for culture. The clones were picked for identification and sequencing confirmation, and the heavy chain and light chain expression plasmids based on pCDNA3.1 (+) were constructed respectively. The heavy chain and light chain expression plasmids were extracted separately using the endotoxin-free plasmid extraction kit (purchased from Biomiga, BW-PD3511-02), and the two were mixed 1:1. Take 1.0 mg of the mixed plasmid and dilute it to 25 mL with Wayne293 expression medium (purchased from Zhongshan Kangsheng, A21501); take 3.0 mg of PEI (linear, 25KD, Polysciences, Inc.), dilute it to 25 mL with Wayne293 expression medium, add it to the plasmid solution, mix well, and incubate at room temperature for 30 minutes. Take Hek293F cells (viability>95%) in logarithmic phase growth, count; centrifuge at 1100 rpm for 10 minutes, discard the supernatant, and resuspend the cells with 450 mL of Wayne293 expression medium. Add the above plasmid-PEI mixture to the cell suspension, culture it in a shaker incubator at 37°C and 5% CO2 for 7 days, centrifuge and take the supernatant for subsequent protein purification.

[0068] Table 1 Amino acid sequence and coding sequence of multi-domain fusion protein

[0069]

[0070]

[0071] Example 2 Purification of multi-domain fusion protein

[0072] 2.1 Anti-PD-L1 single domain antibody is located at the N-terminus of the heavy chain of anti-VEGF monoclonal antibody

[0073] The cell fermentation supernatant was adjusted to pH 7.0 and loaded onto a Protein A affinity chromatography column (Borgron Biotechnology Co., Ltd.). The equilibrium solution was 20mM PB, 0.15M NaCl (pH = 7.0), and eluted with 100% 0.1M Gly-HCl (pH = 3.0); 10% 1M Tris-HCl (pH = 8.5) was added to the eluent in advance. The 100% eluent was diluted to a conductivity of <3ms / cm, and the supernatant was adjusted to pH 7.0 and loaded onto a DSP chromatography column (Borgron Biotechnology Co., Ltd.), eluted at 15% and 100% (20mM PB, 0.5M NaCl, pH 7.0). The 15% elution fraction was obtained, which was the target protein. The protein concentration was determined by UV280 method.

[0074] 2.2 Anti-PD-L1 single domain antibody is located at the N-terminus of the light chain of anti-VEGF monoclonal antibody

[0075] The cell fermentation supernatant was adjusted to pH 7.0 and then loaded onto a Protein A affinity chromatography column (Borgron Biotechnology Co., Ltd.). The equilibrium solution was 20mM PB, 0.15M NaCl (pH = 7.0), and eluted with 100% 0.1M Gly-HCl (pH = 3.0); 10% 1M Tris-HCl (pH = 8.5) was added to the eluent in advance. The 100% eluent was diluted to a conductivity of 4ms / cm and loaded onto a Super Q (TOSOH) chromatography column. The equilibrium solution was 20mM Tris, pH 8, and the eluent was 500mM NaCl + 20mM Tris (pH = 8.0). The 35% and 100% elutions were removed by flow-through to obtain the 35% elution fraction, which was the target protein. The protein concentration was determined by UV280.

[0076] Purity detection was performed using SEC-HPLC-UV analysis. Detector: Agilent 1100LC; Detection wavelength: 214nm; Mobile phase: 150mM pH7.0 PB + 5% isopropanol; Chromatographic column: Superdex 200Increase 5 / 150GL; Run time: 15 minutes; Column temperature 25°C. The test results showed that the purity was greater than 95%.

[0077] Purification of PD-L1-Fc fusion protein (SEQ ID NO.47) and Fc-TGFβRII fusion protein (SEQ ID NO.48): The cell fermentation supernatant was adjusted to pH 7.0 and loaded onto a Protein A affinity chromatography column (Borgron Biotechnology Co., Ltd.), the equilibrium solution was 20 mM PB, 0.15 M NaCl (pH = 7.0), and eluted with 100% 0.1 M Gly-HCl (pH = 3.0); 10% 1 M Tris-HCl (pH = 8.5) was added to the eluate in advance for neutralization.

[0078] Example 3 Identification of the function of multi-domain fusion proteins in vitro

[0079] 3.1 In vitro activity detection of anti-PD-L1 single domain antibody fragments:

[0080] The CD5L-OKT3scFv-CD14 gene sequence (GenBank: ADN42857.1) was synthesized and digested with HindIII-EcoRI (Takara) and inserted into the vector pCDNA3.1 to construct pCDNA3.1-antiCD3TM. The human PD-L1 gene (GenBank: NM_014143.2) was used as a template, and the PD-L1 fragment was amplified with high fidelity and recombined and connected into pCDNA3.1-antiCD3TM to construct pCDNA3.1-antiCD3TM-PDL1. CHO cells (Thermo) were transfected and then selected with G418 for 10-14 days to produce the stable cell line CHO-antiCD3TM-PDL1.

[0081] The fragment obtained by amplification of the human PD1 gene (GenBank: NP_005009.2) was recombined with the PB513B1-dual-puro vector (Ubao Bio) digested with HindIII-BamHI (Takara) to construct the plasmid pB-PD1. High-fidelity amplification was performed using pGL4.30 (Ubao Bio) as a template, and the obtained fragment was recovered and recombined with the pB-PD1 vector digested with SfiI-XbaI (Takara) to construct the pB-NFAT-Luc2p-PD1 plasmid. After the plasmid was successfully constructed, the plasmid was extracted with the endotoxin-free plasmid extraction kit (Biomiga) for transfection of Jurkat cells (Stem Cell Bank of the Chinese Academy of Sciences). Referring to the method in patent CN107022571A, Jurkat cells were treated to a relatively adherent state by using 0.1 mg / ml poly-D-lysine, and then transfected according to the transfection instructions in the lipofectamine transfection kit (Lipofectamine 3000; Invitrogen); on the third day, RPMI1640 medium (Thermo) containing 10% FBS and 2.5 μg / ml puromycin was used for pressure screening; thereafter, the medium was supplemented at regular intervals, and the puromycin content was gradually increased to 4 μg / ml after the cell viability was restored. Finally, a monoclonal Jurkat-NFAT-Luc2p-PD1 cell line was obtained.

[0082] Take CHO-antiCD3TM-PDL1 and Jurkat-NFAT-Luc2p-PD1 cells and count them, and adjust the cell density to 4×10 6 / ml, add 25μl to each cell in each well of a 96-well plate; dilute the fusion protein samples prepared in Example 2 with 1% BSA gradient, and add 50μl to the cells; after culturing for 6 hours at 37°C and 5% CO2, add 10μl of luciferase substrate (Promega, E2620) to each well, shake on an oscillator for 2 minutes, and read the results. The operation is as described in the kit instructions.

[0083] 3.2 In vitro activity detection of antagonistic VEGF fragments:

[0084] HEK293 cells were plated in 6-well cell culture plates, with 1.0 × 10 cells per well. 6 The cells were cultured overnight in a 37°C, 5% CO2 incubator. The transfection system was prepared according to the instructions of the transfection reagent, including 1.0μg of pcDNA-KDR plasmid and 4μg of pGL4.30 plasmid. After 48 hours of transfection, the cells were expanded to a 10cm cell culture dish and G418 200μg / ml and Hygromycin 100μg / ml were added. Fresh pressurized culture medium was replaced every 3 days until obvious clones grew out. The cells were digested and plated on a 96-well cell culture plate. After a single clone grew out, 0.1μg / ml VEGF was used to stimulate for 6 hours and then the chemiluminescence was detected. The clones with obvious signal response were selected and continued to be expanded and cultured. Finally, the monoclonal HEK293-NFAT-KDR was obtained. HEK293-NFAT-KDR cells were plated at a density of 40,000 / well and digested with Accutase; the digested cells were collected and centrifuged at 1000rpm for 5 minutes; the supernatant was discarded and the cells were resuspended in analysis medium (DMEM+5% FBS); the cells were counted and the cell density was adjusted to 1.6×10 6 / ml; spread 96-well cell culture plates, 25ul per well; use analytical culture fluid to prepare VEGF solution, the concentration is 60ng / ml; add to the cell culture plate, 25ul per well; use analytical culture fluid to prepare the fusion protein prepared in Example 2, add to the cell culture plate, 25ul per well; incubate at 37°C, 5% CO2 for 6h; add 10ul Bright-Glo luciferase detection reagent (Promega, E2620) to each well, shake for 2 minutes, transfer 80ul lysate to the ELISA white plate, and read with an ELISA reader.

[0085] 3.3 In vitro cell activity detection of TGF-β binding fragments:

[0086] Mouse breast cancer 4T1 cells were cultured until they were about 90% confluent (10 cm dish), digested with trypsin, and plated at 4 × 10 5 The cells were plated into 6-well plates and cultured overnight. The pGL4.48[luc2P SBE Hygro] plasmid samples were extracted and used Transfection of 4T1 cells. 24 hours after transfection, the obtained TGFβ-4T1 cells were digested with trypsin and transferred to a 10 cm culture dish. The cells were pressure screened using RPMI 1640 medium containing 10% FBS and 150ug / ml hygromycin (InvivoGen, Cat no.: ant-hg-1). After 10 to 15 days of pressure screening, TGFβ-4T1 cells were plated at 2 / well for monoclonal screening. The monoclonal cells were stimulated with TGFβ1 (Novoprotein, 10ug, Cat no.: CA59) to verify the transfection effect of the monoclonal cells, and finally TGFβ-4T1 monoclonal cells were obtained.

[0087] TGFβ-4T1 cells were grown to about 90%, and about 2.5 ml of 0.25% trypsin was added for digestion at room temperature for 2 minutes; the cells attached to the culture dish were blown down and dispersed by blowing in the trypsin solution. The whole digestion process took ~5 minutes, and complete culture medium (RPMI 1640 + 10% FBS) was added to terminate the digestion, and the cells were continued to be blown until the cells were evenly dispersed; the cells were transferred to a 50ml centrifuge tube and centrifuged at 1000rpm for 5 minutes; the supernatant was discarded, 2 ml of complete culture medium was added to resuspend the cells, and the cell density was measured by a cell counter; the cells were diluted with complete culture medium (RPMI 1640 + 10% FBS) to a cell density of 2×10 5 / ml; the diluted cells (density 2×10 5 / ml) were plated (96-well plate), 100ul per well, and the cell density was 2×10 4 / well, the 96-well plate was placed in a 37°C incubator for overnight culture; the fusion protein sample prepared in Example 2 was diluted to the specified concentration using RPMI 1640 + 0.2% FBS culture medium (containing 2ng / ml TGFβ1) (each protein sample was placed at room temperature for 1h after dilution); the supernatant of TGFβ-4T1 cells cultured in a 37°C incubator overnight was discarded, 50ul RPMI 1640 + 0.2% FBS culture medium was added, and then 50μl of protein solutions of different concentrations were added; the 96-well plate was placed in a 37°C incubator for further incubation for 3h, then 10ul Bright-Glo luciferase detection reagent (Promega, E2620) was added and shaken for 3min; the microplate reader was used to read the results.

[0088] The measurement results of the anti-PD-L1 activity, anti-VEGF activity, and anti-TGFβ activity of each multi-domain fusion protein are shown in Table 2. As shown in Table 2, each multi-domain fusion protein has good in vitro cell activity.

[0089] Table 2 In vitro cell activity of multi-domain fusion proteins

[0090]

[0091]

[0092] Example 4 Pharmacokinetics of multi-domain fusion proteins in C57BL / 6 mice

[0093] C57BL / 6 mice were divided into 4 groups, including low-dose (1 mg / kg) and high-dose (10 mg / kg) Avastin (Roche), low-dose (1 mg / kg) and high-dose (10 mg / kg) TAF-6, with 8 mice in each group, half male and half female. The mice were given a single injection of the drug through the tail vein, and the pharmacokinetic samples were collected crosswise at different time points. The collection time was 1h, 6h, 24h, 48h, 78h, 120h, 144h, 168h, 192h, and 216h before and after the drug. The serum drug concentration in the pharmacokinetic samples was quantitatively detected by ELISA. VEGF-coated plates, secondary antibodies Goat anti-Human IgG Fc, HRP-conjugated drugs, and TMB method was used for detection. The signal and concentration value relationship of the standard curve were regressed into concentration values, and the main pharmacokinetic parameters were calculated using the non-compartmental model of PK Solver software.

[0094] The results are as follows Figure 1 As shown, the pharmacokinetic parameters of C57BL / 6 mice were similar when Avastin and TAF-6 were administered to high and low dose groups. The dosage ratio of Avastin low and high dose groups was 1:10. max The ratio is 1:9.3, AUC last The ratio is 1:8.9, T max All were 1h, exposure (C max and AUC last ) increased in a dose-proportional manner. The ratio of TAF-6 low-dose to high-dose groups was 1:10, C max The ratio is 1:8.6, AUC last The ratio is 1:8.5, Tmax is 1h, and the exposure (C max and AUC last ) increased in a dose-proportional manner. Therefore, AUC and C max The difference in AUC between Avastin and TAF-6 was inferred to be the PD-L1 target-mediated clearance effect (TMDD).

[0095] Example 5 Tumor inhibitory activity of multi-domain fusion protein in PBMC humanized breast cancer MDA-MB-231 mice

[0096] The in vivo efficacy of the multi-domain fusion protein of the present invention was determined by modeling MDA-MB-231 (human breast cancer) cells in human PBMC immune system humanized mice (M-NSG mice). Female M-NSG mice aged 6-8 weeks were selected, and the mice were inoculated with MDA-MB-231 cells (10*10E6+matrigel 25%). PBMC (5*10E6 / 0.2ml) was injected into the tail vein on the 7th day. The tumor volume and body weight were then observed. The tumor volume of 140-260mm was selected. 3 Mice between 1 and 2 weeks old were randomly divided into 6 groups according to their tumor volume and body weight, with 7 mice in each group, and drug administration began on the day of grouping. Tumor-bearing mice with tumors that were too large / too small were eliminated. Twice a week, intraperitoneal injections were given: PBS, isotype control IgG1, positive control Tecentriq (Roche), TAF-6, TAF-7 and combined administration (see Table 3 for details of the regimen), for a total of about 3 weeks. PD-L1-Fc fusion protein (SEQ ID NO.47) is a fusion protein of anti-PD-L1 single domain antibody and human IgG Fc (the anti-PD-L1 single domain antibody is located at the N-terminus of Fc), and Fc-TGFβRII fusion protein (SEQ ID NO.48) is a fusion protein of human IgG Fc and TGFβRII (TGFβRII is located at the C-terminus of Fc).

[0097] Before grouping and before the end of the experiment, blood was collected from the orbital vein of the mice. The FACS test results showed that human CD45-positive cells were present in the peripheral blood of the mice in each group, and the CD45 ratio increased over time, indicating that the mouse immune system was successfully humanized. During the experiment, the weight of the animals in Group 3 and Group 4 (measured twice a week) was generally stable, and no experimental animals died. The tumor volume of Group 3 and Group 4 (measured twice a week) was smaller than that of Group 6 combined administration, and significantly smaller than that of Group 2 corresponding single-drug Tecentriq. The results are as follows Figure 2 shown.

[0098] Table 3

[0099]

[0100] Example 6 Tumor inhibitory activity of multi-domain fusion proteins in PBMC humanized breast cancer MDA-MB-231 mice

[0101] Human breast cancer MDA-MB-231 tumors were inoculated subcutaneously in the right anterior flank of female NCG mice. PBMC cells were inoculated into the mice one day after tumor inoculation. When the tumor grew to 53 mm 3The mice were divided into groups and given drugs at about 12 hours. There were 6 groups with 10 mice in each group, including Vehicle group, TAF-6 low (2 mg / kg, ip, tiw×9) group, TAF-6 medium (6 mg / kg, ip, tiw×9) group, TAF-6 high (18 mg / kg, ip, tiw×9) group, Tecentriq (4 mg / kg, ip, tiw×9) group, and Avastin (4 mg / kg, ip, tiw×9) group. The tumor volume and body weight were measured every week, and the relationship between the changes in body weight and tumor volume of tumor-bearing mice and the administration time was recorded.

[0102] Blood was collected from the orbital venous plexus 2 days before grouping and at the end of the experiment. FACS detection showed that human CD45-positive cells were present in the peripheral blood of mice in each group, and the proportion of CD45 increased over time. At the end of the experiment, the tumor-bearing mice were euthanized, the tumors were removed, weighed, and photographed, and serum and tumors were collected and fixed. Tumor growth inhibition rate TGI was calculated TV (%) and statistical analysis was performed: TAF-6 low group, TAF-6 medium group, TAF-6 high group, Group, The tumor growth inhibition rates of the groups were 41%, 34%, 60%, 23%, and 32%, respectively. The tumor volumes of all groups were significantly smaller than those of the Vehicle group (all p<0.05), and the tumor volume of the TAF-6 high group was significantly smaller than that of the group (p<0.01), There was no significant difference in tumor volume between the groups (p>0.05). Figure 3 shown.

[0103] In summary, the test drug TAF-6 has a significant anti-tumor effect on the PBMC humanized breast cancer MDA-MB-231 subcutaneous transplant tumor model and effectively inhibits tumor growth. Its anti-tumor effect is significantly better than Tecentriq, and the tumor inhibition effect increases with increasing dose.

[0104] In another independent experiment with the same tumor model, the anti-tumor activity of the test drug and the positive drug M7824 analog (prepared by our laboratory according to M7824 patent US9676863B2) was compared. Four groups were set up, with 6 mice in each group, namely: Vehicle group, TAF-6 (4.2 mg / kg, ip, tiw x 8 times; later the dose was adjusted to 8.4 mg / kg, ip, tiw x 4 times) group, M7824 analog (3.6 mg / kg, ip, tiw x 8 times; later the dose was adjusted to 7.2 mg / kg, ip, tiw x 4 times) group, Avastin (3 mg / kg, ip, tiw x 8 times; later the dose was adjusted to 6 mg / kg, ip, tiw x 4 times) group. The results are as follows: Figure 4 As shown, at equimolar concentrations, the anti-tumor effect of TAF-6 was significantly superior to that of the M7824 analog.

[0105] Example 7 Tumor inhibitory activity of multi-domain fusion protein in PBMC humanized lung cancer Calu-6 mice

[0106] Calu-6 human lung cancer cells were inoculated subcutaneously in the right anterior flank of male NCG mice. PBMC cells were inoculated into the mice 4 days before tumor cell inoculation. When the tumor grew to 50 mm 3 The mice were divided into groups and dosed at about 10 pm, with a total of 7 groups, 8 mice in each group, namely: Vehicle group, TAF-6 low (2 mg / kg, ip, tiw×10) group, TAF-6 medium (7 mg / kg, ip, tiw×10) group, TAF-6 high (25 mg / kg, ip, tiw×10) group, Tecentriq (5 mg / kg, ip, tiw×10) group, Avastin (5 mg / kg, ip, tiw×10) group, Tecentriq+Avastin (5+5 mg / kg, ip, tiw×10) group. Tumor volume and body weight were measured every week, and the relationship between the changes in body weight and tumor volume of tumor-bearing mice and the time of administration was recorded. At the end of the experiment, the tumor-bearing mice were euthanized, the tumors were removed, weighed, and photographed, and serum and tumors were collected. The tumor growth inhibition rate TGI was calculated. TV (%) and statistical analysis was performed.

[0107] Three days before grouping and at the end of the experiment (PG-D23), blood was collected from the orbital vein of mice. FACS test results showed the presence of human CD45-positive cells in the peripheral blood of mice in each group, and the CD45 ratio increased over time, indicating that the mouse immune system was successfully humanized.

[0108] During the treatment period, the mice in each group ate and drank normally, their body weights were generally stable, and no experimental animals died.

[0109] At the end of the experiment (PG-D23), the tumor growth inhibition rates of the TAF-6 low group, TAF-6 medium group, TAF-6 high group, Tecentriq group, Avastin group, and Tecentriq + Avastin group were 62%, 62%, 75%, 13%, 34%, and 32%, respectively. Except for the Tecentriq group, the tumor volume of each group was significantly smaller than that of the Vehicle group (all p < 0.01). The tumor volumes of the TAF-6 low, medium, and high groups were significantly smaller than those of the Tecentriq group, Avastin group, and Tecentriq + Avastin group (all p < 0.01). The results are shown in Tables 4 and Figure 5 shown.

[0110] In summary, the test drug TAF-6 has a significant anti-tumor effect on the PBMC humanized lung cancer Calu-6 subcutaneous transplant tumor model, effectively inhibiting tumor growth. The tumor inhibition effect is significantly better than Tecentriq, Avastin and the combination of Tecentriq and Avastin, and the tumor inhibition effect increases with increasing dose.

[0111] Table 4 Antitumor effect of the test substances on human lung cancer Calu-6 (tumor volume)

[0112]

[0113] Note: a. Mean ± SE.

[0114] In another independent experiment with the same tumor model, the anti-tumor activity of the tested drug was compared with that of the positive drug M7824 analog. Four groups were set up, with 6 mice in each group, namely: Vehicle group, TAF-6 (7 mg / kg, ip, TIW x 8 times) group, M7824 analog (6 mg / kg, ip, TIW x 8 times) group, and Avastin (5 mg / kg, ip, TIW x 8 times) group. The results are as follows: Figure 6 As shown, at equimolar concentrations, the anti-tumor effect of TAF-6 was significantly superior to that of M7824 analogs and Avastin.

[0115] Example 8 Tumor Suppressive Activity of Multi-Domain Fusion Protein in PBMC Humanized Colon Cancer HCT116 Mice

[0116] The in vivo efficacy of the multi-domain fusion protein of the present invention was determined by modeling HCT-116 (human colon cancer) cells in human PBMC immune system humanized mice (NOG mice). Female NOG mice aged 7-9 weeks were selected, and the mice were inoculated with HCT-116 cells (3*10E6+matrigel). On the third day after tumor cell inoculation, PBMC (5*10E6 / 0.2ml) was injected into the tail vein. The tumor volume and body weight were then observed. The tumor volume was 60-100mm. 3 Mice between 40 and 60 days old were randomly divided into 6 groups according to their tumor volume and body weight, with 8 mice in each group. Drug administration began on the day of grouping: Vehicle group, TAF-6 low (2 mg / kg, ip, tiw×3) group, TAF-6 medium (7 mg / kg, ip, tiw×3) group, TAF-6 high (25 mg / kg, ip, tiw×3) group, Tecentriq (5 mg / kg, ip, tiw×3) group, and Tecentriq+Avastin (5+5 mg / kg, ip, tiw×3) group. Tumor volume and body weight were measured twice a week, and the changes in body weight and tumor volume of tumor-bearing mice and the relationship with the administration time were recorded. At the end of the experiment, the tumor-bearing mice were euthanized, the tumors were removed, weighed, and photographed, and serum and tumors were collected. The tumor growth inhibition rate TGI was calculated. TV (%) and statistical analysis was performed.

[0117] Before grouping and before the end of the experiment, blood was collected from the orbital vein of mice. FACS test results showed the presence of human CD45-positive cells in the peripheral blood of mice in each group, and the CD45 ratio increased over time, indicating that the mouse immune system was successfully humanized.

[0118] Antitumor activity Figure 7 As shown. The test drug TAF-6 has a significant anti-tumor effect on the PBMC humanized colon cancer HCT116 subcutaneous transplant tumor model, effectively inhibiting tumor growth, and the high-dose and medium-dose groups have significantly better tumor inhibition effects than Tecentriq. At the same molar concentration dose, that is, TAF-6 medium (7mg / kg, ip, tiw×3) group vs. Tecentriq+Avastin (5+5mg / kg, ip, tiw×3) group, TAF-6 can still be observed to be not inferior to, or even superior to, the Tecentriq+Avastin group.

[0119] Example 9 Tumor Suppressive Activity of Multi-Domain Fusion Protein in PBMC Humanized Hepatocarcinoma Huh-7 Mice

[0120] Human hepatocellular carcinoma Huh-7 cells were inoculated subcutaneously in the right anterior flank of male NCG mice. PBMC cells were inoculated into the mice 45 days before tumor cell inoculation. When the tumor grew to 50 mm3 The mice were divided into groups and dosed at about 12 hours. There were 5 groups with 10 mice in each group, namely: Isotype group, TAF-6 low (2 mg / kg, ip, tiw×8) group, TAF-6 high (7 mg / kg, ip, tiw×8) group, Tecentriq (5 mg / kg, ip, tiw×8) group, and Avastin (5 mg / kg, ip, tiw×8) group. The tumor volume and body weight were measured twice a week, and the changes in the weight and tumor volume of tumor-bearing mice and the relationship with the administration time were recorded. At the end of the experiment, the tumor-bearing mice were euthanized, the tumors were removed, weighed, and photographed, and serum and tumors were collected. The tumor growth inhibition rate TGI was calculated. TV (%) and statistical analysis was performed.

[0121] Before grouping and at the end of the experiment, blood was collected from the orbital venous plexus of mice. FACS test results showed the presence of human CD45-positive cells in the peripheral blood of mice in each group, and the CD45 ratio increased over time, indicating that the mouse immune system was successfully humanized.

[0122] During the administration period, the mice in each group ate and drank normally, and their body weight remained generally stable.

[0123] Before the end of the experiment (PG-D18), the tumor growth inhibition rates of the TAF-6 low group, TAF-6 high group, Tecentriq group, and Avastin group were 57%, 74%, 18%, and 67%, respectively. Except for the Tecentriq group, the tumor volume of each group was significantly smaller than that of the Isotype group (all p<0.01), the tumor volume of the TAF-6 high group was significantly smaller than that of the Tecentriq group (all p<0.01), and the tumor volume of the Avastin group was significantly smaller than that of the Tecentriq group (p<0.05). Figure 8 shown.

[0124] In summary, the test drug TAF-6 has a significant anti-tumor effect on the PBMC humanized liver cancer Huh-7 subcutaneous transplant tumor model, effectively inhibiting tumor growth. The anti-tumor effect is significantly better than Tecentriq, and the tumor inhibition effect increases with increasing dose.

[0125] In another independent experiment with the same tumor model, the anti-tumor activity of the test drug was investigated and compared with the positive drug M7824 analog. Four groups were set up, with 6 mice in each group, namely: Vehicle group, TAF-6 (7 mg / kg, ip, tiw x 9; later the dose was adjusted to 14 mg / kg, ip, tiw x 2) group, M7824 analog (6 mg / kg, ip, tiw x 9; later the dose was adjusted to 12 mg / kg, ip, tiw x 2) group, Avastin (5 mg / kg, ip, tiw x 9; later the dose was adjusted to 10 mg / kg, ip, tiw x 2) group. The results are as follows: Fig. 9 As shown, the anti-tumor effect of TAF-6 is significantly better than that of the M7824 analog.

[0126] Example 10 Tumor inhibitory activity of multi-domain fusion proteins in PBMC humanized sarcoma HT1080 mice

[0127] Human sarcoma HT1080 cells were inoculated subcutaneously in the right anterior flank of male NCG mice. PBMC cells were inoculated into the mice 7 days before tumor cell inoculation. When the tumor grew to 56 mm 3 The mice were divided into five groups and each group had 8 mice, including Vehicle group, TAF-6 low (2 mg / kg, ip, tiw×9) group, TAF-6 medium (7 mg / kg, ip, tiw×9) group, TAF-6 high (25 mg / kg, ip, tiw×9) group, and Tecentriq (5 mg / kg, ip, tiw×9) group. The tumor volume and body weight were measured every week, and the relationship between the changes in body weight and tumor volume of tumor-bearing mice and the administration time was recorded.

[0128] At the end of the experiment, the tumor-bearing mice were euthanized, the tumors were removed, weighed, photographed, and serum and tumors were collected. TV (%) and statistical analysis was performed.

[0129] Before grouping and at the end of the experiment, blood was collected from the orbital venous plexus of mice. FACS test results showed the presence of human CD45-positive cells in the peripheral blood of mice in each group, and the CD45 ratio increased over time, indicating that the mouse immune system was successfully humanized.

[0130] Before the end of the experiment (PG-D19), the tumor growth inhibition rates of the TAF-6 low group, TAF-6 medium group, TAF-6 high group, and Tecentriq group were 19%, 33%, 41%, and 28%, respectively. The tumor volumes of the TAF-6 medium group and the Tecentriq group were significantly smaller than those of the Vehicle group (all p<0.05). There was no significant difference in tumor volume among the groups (p>0.05). The results are as follows Fig.10 shown.

[0131] In summary, the present invention effectively overcomes various shortcomings of the prior art and has high industrial utilization value.

[0132] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. A fusion protein, comprising an anti-PD-L1 single domain antibody fragment, an antagonist VEGF fragment, and a TGF-β binding fragment, wherein the complementarity determining region of the anti-PD-L1 single domain antibody fragment comprises: The amino acid sequence is CDR1 shown in one of SEQ ID NOs. 1 to 5, CDR2 shown in one of SEQ ID NOs. 6 to 9, and CDR3 shown in one of SEQ ID NOs. 10 to 15.

2. The fusion protein according to claim 1, characterized in that The complementarity determining region of the anti-PD-L1 single domain antibody fragment comprises: The amino acid sequence is CDR1 shown in SEQ ID NO.1, CDR2 shown in SEQ ID NO.6, and CDR3 shown in SEQ ID NO.10; or The amino acid sequence is CDR1 shown in SEQ ID NO.2, CDR2 shown in SEQ ID NO.7, and CDR3 shown in SEQ ID NO.11; or The amino acid sequence is CDR1 shown in SEQ ID NO.3, CDR2 shown in SEQ ID NO.7, and CDR3 shown in SEQ ID NO.12; or The amino acid sequence is CDR1 shown in SEQ ID NO.4, CDR2 shown in SEQ ID NO.8, and CDR3 shown in SEQ ID NO.13; or The amino acid sequence is CDR1 shown in SEQ ID NO.2, CDR2 shown in SEQ ID NO.7, and CDR3 shown in SEQ ID NO.14; or The amino acid sequence is CDR1 shown in SEQ ID NO.5, CDR2 shown in SEQ ID NO.9, and CDR3 shown in SEQ ID NO.

15.

3. The fusion protein according to claim 1, characterized in that The anti-PD-L1 single domain antibody fragment comprises: a) a polypeptide fragment whose amino acid sequence is shown in one of SEQ ID No. 16 to 21; or, b) a polypeptide fragment having an amino acid sequence with more than 95% sequence identity with one of SEQ ID No. 16 to 21 and having the function of the polypeptide fragment defined in a); and / or, the anti-PD-L1 single domain antibody fragment is derived from alpaca; And / or, the anti-PD-L1 single domain antibody fragment is humanized.

4. The fusion protein according to claim 1, characterized in that The antagonist VEGF fragment is bevacizumab. Preferably, the antagonist VEGF fragment comprises: c) a polypeptide fragment whose amino acid sequence is shown in one of SEQ ID No. 22 to 23; or, d) a polypeptide fragment having an amino acid sequence with more than 95% sequence identity with one of SEQ ID No. 22 to 23 and having the function of the polypeptide fragment defined in c); and / or, the antagonistic VEGF fragment is derived from mouse; And / or, the antagonist VEGF fragment is humanized.

5. The fusion protein according to claim 1, characterized in that The TGF-β binding fragment is a TGF-βRⅡ extracellular domain fragment. Preferably, the TGF-β binding fragment includes: e) a polypeptide fragment with an amino acid sequence as shown in SEQ ID No. 24; or, f) a polypeptide fragment having an amino acid sequence with more than 95% sequence identity with SEQ ID No. 24 and having the function of the polypeptide fragment defined in e); And / or, the TGF-β binding fragment is derived from human.

6. The fusion protein according to claim 1, characterized in that The fusion protein also includes a connecting peptide fragment. Preferably, the connecting peptide fragment is rich in G, S and / or A. More preferably, the connecting peptide is selected from a flexible polypeptide chain consisting of G glycine and / or S serine and / or A alanine, and the length of the connecting peptide is 3 to 30 amino acids.

7. The fusion protein according to claim 1, characterized in that The amino acid sequence of the fusion protein includes SEQ ID NO.

23. A sequence as shown in one of SEQ ID NOs. 25-33; Or, the amino acid sequence of the fusion protein includes the sequence shown in SEQ ID NO.25 and SEQ ID NO.26, the sequence shown in SEQ ID NO.25 and SEQ ID NO.27, the sequence shown in SEQ ID NO.25 and SEQ ID NO.28, the sequence shown in SEQ ID NO.25 and SEQ ID NO.29, the sequence shown in SEQ ID NO.30 and SEQ ID NO.27, the sequence shown in SEQ ID NO.30 and SEQ ID NO.29, the sequence shown in SEQ ID NO.31 and SEQ ID NO.23, the sequence shown in SEQ ID NO.32 and SEQ ID NO.23, and the sequence shown in SEQ ID NO.33 and SEQ ID NO.

23.

8. An isolated polynucleotide encoding the fusion protein according to any one of claims 1 to 6.

9. Use of the fusion protein according to any one of claims 1 to 7 in the preparation of a drug for treating tumors.

10. The use according to claim 9, characterized in that The tumor is selected from the group consisting of lung cancer, melanoma, gastric cancer, ovarian cancer, colon cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, classical Hodgkin's lymphoma, hematological malignancies, sarcoma, head and neck cancer, and nasopharyngeal carcinoma.